Search - tctmd.com

Displaying 101 - 120 of 1389

Sort: Relevancy | Date

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

DES Best for In-Stent Restenosis, but DCBs Also Viable

Michael O'Riordan

August 13, 2024

News Daily News

Sudden Deaths After Acute MI Have Dropped, but Early Weeks Remain Risky

Yael L. Maxwell

August 08, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News SCCT 2024

AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk

Todd Neale

July 25, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

News Industry News

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

May 29, 2024

News Conference News EuroPCR 2024

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

Shelley Wood

May 16, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Conference News SCAI 2024

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

L.A. McKeown

May 03, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Features

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Caitlin E. Cox

May 02, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Advertisement

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

DES Best for In-Stent Restenosis, but DCBs Also Viable

Sudden Deaths After Acute MI Have Dropped, but Early Weeks Remain Risky

August 2024 Dispatch for the CV Team

AI Assessment of Plaque, Hemodynamics May ID Lesion-Specific ACS Risk

July 2024 Dispatch for the CV Team

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

CellProthera announces positive Phase I/IIb data for ProtheraCytes® cell therapy in acute myocardial infarction

ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

AI Picks Up on Info Operators Miss on Angiograms: AI-ENCODE

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content